• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Symphogen

edit

Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.

Milestones

edit

• 
  Symphogen added Thomas Feldthus as Co-founder and CFO.
  Posted 5/26/09 at 11:58pm
• 
  Symphogen added John Haurum as Co-founder and CSO.
  Posted 5/26/09 at 11:58pm
• 
  Symphogen added Kirsten Drejer as Co-founder and CEO.
  Posted 5/26/09 at 11:58pm
• 
  Symphogen received $135M in Series F funding. (2/14/11)
  Posted 2/14/11 at 4:01am via onbiovc.com
• 
  Symphogen received $131M (€100M) in Unattributed funding. (1/6/11)
  Posted 1/6/11 at 6:37pm via finsmes.com
• 
  Symphogen received $25M in Series D funding. (1/10/06)
  Posted 4/20/10 at 7:35pm via sciencebusiness.net
• 
  Symphogen received in Unattributed funding. (6/10/08)
  Posted 5/27/09 at 12:04am
• 
  Symphogen received $42.1M (€33M) in Unattributed funding. (2/2/09)
  Posted 4/17/09 at 4:25am via symphogen.com
• 
  Symphogen — Symphogen lines up record $131M venture round. (1/6/11)
  Posted 1/17/11 at 5:44am via fiercebiotech.com

Videos

Screenshots

edit

Above: Home page
Uploaded: 5/13/09

Sources

1. Symphogen gets $25M for clinical trials for bleeding treatment (bulletin.sciencebusiness.net) [edit]
2. Capital Funding Report [edit]
3. Symphogen secures € 33 million financing to support clinical development of antibody products (symphogen.com) [edit]
4. Symphogen Closes €100M Round of Financing (finsmes.com) [edit]
5. Symphogen, AS: Series F $135.4M (onbiovc.com) [edit]
6. Symphogen lines up record $131M venture round (fiercebiotech.com) [edit]